Insulin Lispro

Brand names: Humalog · Active ingredient: Insulin Lispro

In short: Insulin Lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Forms & strengthsInjection: 100 units/mL (U-100) clear and colorless solution available as: 10 mL multiple-dose vial 3 mL single-patient-use KwikPen prefilled pen 3 mL single-patient-use Junior KwikPen prefilled pen
LabelA-S Medication Solutions
Label updatedSep 21, 2026

What is Insulin Lispro used for?

Insulin Lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Insulin Lispro dosage

Always check insulin labels before administration. This product is HUMALOG (insulin lispro) .

Inspect Insulin Lispro visually before use. It should appear clear and colorless. Do not use Insulin Lispro if particulate matter or coloration is seen.

Use Insulin Lispro prefilled pens with caution in patients with visual impairment that may rely on audible clicks to dial their dose.

Do NOT mix Insulin Lispro with other insulins when using a continuous subcutaneous infusion pump.

Do NOT perform dose conversion when using any Insulin Lispro prefilled pens. The dose window shows the number of insulin units to be delivered and no conversion is needed.

Subcutaneous Injection

Administer the dose of Insulin Lispro within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks.

Rotate the injection site within the same region from one injection to the next (abdominal wall, thigh, upper arm, or buttocks) to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis .

During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring .

Insulin Lispro administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin.

The Insulin Lispro KwikPen dials in 1 unit increments and delivers a maximum dose of 60 units per injection.

The Insulin Lispro Junior KwikPen dials in 0.5 unit increments and delivers a maximum dose of 30 units per injection.

Subcutaneous Injection: Diluted Insulin Lispro

Insulin Lispro may be diluted with Sterile Diluent for Insulin Lispro for subcutaneous injection ONLY under medical supervision. Dilute one part Insulin Lispro to:

Nine parts diluent to yield a concentration one-tenth that of Insulin Lispro (equivalent to U-10).

One part diluent to yield a concentration one-half that of Insulin Lispro (equivalent to U-50).

Diluted Insulin Lispro for subcutaneous injection may be stored for 28 days when refrigerated at 41°F (5°C) and for 14 days at room temperature up to 86°F (30°C).

Continuous Subcutaneous Infusion (Insulin Pump)

This Insulin Lispro product can be used with continuous subcutaneous insulin infusion pumps labeled for use with Humalog (insulin lispro). Refer to the insulin pump user manual to see if Humalog can be used. Use Insulin Lispro in accordance with the insulin pump system's instructions for use.

Administer Insulin Lispro by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer.

Rotate infusion sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. …

How to take Insulin Lispro — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Never Share an Insulin Lispro Prefilled Pen or Syringe Between Patients

Advise patients that they must never share an Insulin Lispro prefilled pen with another person, even if the needle is changed. Advise patients using Insulin Lispro vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens .

Hyperglycemia or Hypoglycemia

Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of Insulin Lispro therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia.

Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. …

Warnings & precautions

Do not take this medicine if: Insulin Lispro is contraindicated:

during episodes of hypoglycemia .

in patients who are hypersensitive to Insulin Lispro or to any of the excipients in Insulin Lispro .

Insulin Lispro prefilled pens must never be shared between patients, even if the needle is changed. Patients using Insulin Lispro vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia .

Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.

Hypoglycemia is the most common adverse reaction associated with insulins, including Insulin Lispro. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).

Hypoglycemia can happen suddenly, and symptoms may differ in each individual and change over time in the same individual. …

Insulin Lispro side effects

The following adverse reactions are discussed elsewhere:

Hypoglycemia .

Hypoglycemia Due to Medication Errors .

Hypersensitivity Reactions .

Hypokalemia .

Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared with those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.

Common adverse reactions, excluding hypoglycemia, were defined as events that occurred in ≥5% of patients treated with Insulin Lispro or regular human insulin. The frequencies of adverse reactions during Insulin Lispro clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in the tables below.

Insulin Lispro (%)(n=81) | Regular human insulin (%)(n=86)

Flu syndrome | 34.6 | 32.6

Pharyngitis | 33.3 | 33.7

Rhinitis | 24.7 | 29.1

Headache | 29.6 | 22.1

Pain | 19.8 | 16.3

Cough increased | 17.3 | 17.4

Infection | 13.6 | 20.9

Nausea | 6.2 | 15.1

Accidental injury | 8.6 | 11.6

Surgical procedure | 6.2 | 14.0

Fever | 6.2 | 11.6

Abdominal pain | 7.4 | 8.1

Asthenia | 7.4 | 8.1

Bronchitis | 7.4 | 7.0

Diarrhea | 8.6 | 5.8

Dysmenorrhea | 6.2 | 7.0

Myalgia | 7.4 | 5.8

Urinary tract infection | 6.2 | 4.7

Insulin Lispro (%)(n=714) | Regular human insulin (%)(n=709)

Headache | 11.6 | 9.3

Pain | 10.8 | 10.0

Infection | 10.1 | 7.6

Pharyngitis | 6.6 | 8.2

Rhinitis | 8.1 | 6.6

Flu syndrome | 6.2 | 8.2

Surgical procedure | 7.4 | …

Drug interactions

The table below includes clinically significant drug interactions with Insulin Lispro.

Drugs That May Increase the Risk of Hypoglycemia

Drugs: | Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.

Intervention: | Dose adjustment and increased frequency of glucose monitoring may be required when Insulin Lispro is co-administered with these drugs.

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Lispro

Drugs: | Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.

Intervention: | Dose adjustment and increased frequency of glucose monitoring may be required when Insulin Lispro is co-administered with these drugs.

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Lispro

Drugs: | Alcohol, beta-blockers, clonidine, and lithium salts. …

About this medicine

Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5.808 kDa, both identical to that of human insulin.

Insulin lispro has the following primary structure:

Insulin Lispro injection is a sterile, clear, and colorless solution for subcutaneous or intravenous use.

Each mL of Insulin Lispro contains 100 units of insulin lispro, and the inactive ingredients: dibasic sodium phosphate (1.0 mg), glycerin (16 mg), metacresol (3.15 mg), trace amounts of phenol, zinc oxide (content adjusted to provide 0.0197 mg zinc ion), and Water for Injection, USP.

Insulin Lispro has a pH of 7.0 to 7.8.

Hydrochloric acid 10% and/or sodium hydroxide 10% is added to adjust the pH. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2be14cbb-197a-4da8-82c8-2443594e7f6f. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Dulaglutide